Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients

Transplant Proc. 2001 May;33(3):2273-4. doi: 10.1016/s0041-1345(01)01988-1.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antilymphocyte Serum / therapeutic use
  • Daclizumab
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Graft Rejection / epidemiology
  • Graft Rejection / prevention & control*
  • Histocompatibility Testing
  • Humans
  • Immunoglobulin G / administration & dosage
  • Immunoglobulin G / therapeutic use*
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / therapeutic use*
  • Incidence
  • Kidney Transplantation / immunology*
  • Male
  • Methylprednisolone / therapeutic use
  • Muromonab-CD3 / administration & dosage
  • Muromonab-CD3 / therapeutic use*
  • Reoperation
  • Risk Factors

Substances

  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antilymphocyte Serum
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Muromonab-CD3
  • Daclizumab
  • Methylprednisolone